Sign In
15 Dec 2017 07:00
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
Grant of Options
15 December 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces the grant of 2,080,000 share options to its directors and senior management to subscribe for ordinary shares of 10p each in the capital of the Company (the "Options"), as detailed below. All Options were granted on 13 December 2017 (the "Grant Date"), have an exercise price of 38.5 pence each and a ten-year term.
Grants to Executive Directors vest one-third per year on each of the first three anniversaries of the Grant Date on the basis of attainment of certain key performance measures relating to clinical development and other strategic targets, which will be evaluated on the relevant anniversaries. Grants to the Chief Medical Officer and Non-Executive Directors vest one-third per year on each of the first three anniversaries of the Grant Date.
Grants made to Executive Directors under the Realm Therapeutics plc Executive Omnibus Incentive Plan 2016 (the "Plan") are noted below.
Name | Number of Options Granted |
Alex Martin (Chief Executive Officer) | 830,000 |
Marella Thorell (Chief Financial & Operating Officer) | 350,000 |
In addition, Christian Peters (Chief Medical Officer) has been granted 350,000 options.
Grants made to Non-Executive Directors, under individual agreements which are subject to the provisions of the Plan, are noted below. Mr. Zweifach's grant relates to his initial appointment to the Board.
Name | Number of Options Granted |
Charles Spicer (Non-Executive Chairman) | 100,000 |
William Birkett (Senior Independent Non-Executive Director) | 100,000 |
Balkrishan (Simba) Gill (Non-Executive Director) | 100,000 |
Ivan Gergel (Non-Executive Director) | 100,000 |
Sanford (Sandy) Zweifach (Non-Executive Director) | 150,000 |
Following the above grants there is a total of approximately 11.4 million options over ordinary shares outstanding which represents approximately 9.8% of the current issued share capital of the Company.
Contact:
Realm Therapeutics plc
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating Officer
Outside US: +44 (0) 20 3727 1000
US: +1 212 600 1902
Argot Partners
Stephanie Marks
+1 212 600 1902
FTI Consulting
Simon Conway / Mo Noonan
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer
+44 (0) 20 7496 3000
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
Additional Disclosure
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
1 | Details of the person discharging managerial responsibilities/person closely associated with them | ||
a) | Name | 1. Alex Martin 2. Marella Thorell 3. Christian Peters 4. Sanford (Sandy) Zweifach 5. Charles Spicer 6. William Birkett 7. Balkrishan (Simba) Gill 8. Ivan Gergel | |
2 | Reason for notification | ||
a) | Position/status | 1. Chief Executive Officer 2. Chief Financial & Operating Officer 3. Chief Medical Officer 4. Non-Executive Director 5. Non-Executive Chairman 6. Senior Independent Non-Executive Director 7. Non-Executive Director 8. Non-Executive Director | |
b) | Initial notification/Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Realm Therapeutics PLC | |
b) | LEI | n/a | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares in Realm Therapeutics PLC ISIN: GB00B3XBCR18 | |
b) | Nature of transaction | Grant of options over 2,080,000 shares under the Realm Therapeutics plc Executive Omnibus Incentive Plan 2016 and individual agreements | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
1. 38.50 pence
2. 38.50 pence
3. 38.50 pence
4. 38.50 pence
5. 38.50 pence
6. 38.50 pence
7. 38.50 pence
8. 38.50 pence
| 830,000
350,000
350,000
150,000
100,000
100,000
100,000
100,000 | ||
d) | Aggregated information · Aggregated volume · Price | n/a (Single transaction for each recipient of options) | |
e) | Date of the transaction | 13 December 2017 | |
f) | Place of the transaction | Outside a trading venue | |
Follow the stocks
